Table 1

Baseline characteristics and details of PRN ranibizumab injections overall, and for group 1 and 2 eyes, and eyes with and without PCV

Characteristics and injection intervals*Total eyes (N=202)Group 1† (N=149)Group 2‡ (N=53)Eyes with PCV (N=34)Eyes without PCV (N=168)
Male patients67 (33.2)48 (32.2)19 (35.8)10 (29.4)55 (32.7)
Female patients135 (66.8)101 (67.8)34 (64.2)24 (70.6)113 (67.3)
Mean age (years)77.9±6.4 (60–91)78.1±6.5 (60–91)77.4±6.2 (65–91)76.2±7.0 (62–87)78.2±6.3 (60–91)
Interval between injections 1 and 6 (months)10.4±4.6 (5–30)8.3±1.7 (5–11)16.4±4.9 (12–30)8.8±2.3 (6–16)10.8±4.8§ (6–28)
Interval between injections 1 and 8 (months)15.4±5.7 (5–28)12.9±3.0 (8–21)22.4±5.6 (15–34)13.8±3.9 (8–22)15.7±5.9 (8–34)¶
  • *Data are presented as n (%) or mean±SD (range).

  • †<12 months between injections 1 and 6.

  • ‡≥12 months between injections 1 and 6.

  • §p=0.02 versus eyes with PCV.

  • ¶p=0.08 versus eyes with PCV.

  • PCV, polypoidal choroidal vasculopathy; PRN, pro re nata (as needed).